Eric LefkofskyAnd Tempus Slated To Expand Patient Database

Most humans work regular jobs to feel a sense of accomplishment, satisfaction, means of making a living, and – though everybody doesn’t recognize it – to contribute value to society. Although most modern fields are necessary for living modern lives, some are more valuable to society than others – healthcare takes the cake.

Without healthcare, humans would still have average life expectancies of less than 50 years of age. We’d suffer from long-running illnesses that aren’t prevalent in today’s worlds. Further, we’d generally experience lower qualities of living.

Thanks to the perpetual advancement of the field of healthcare, the world is effectively made a better place to live, in perpetuity. Eric Lefkofsky and his firm Tempus are trying their damnedest to improve the world of healthcare even further through data analysis efforts. Here’s just a little bit about Tempus’ and company’s latest works.

Tempus Has Joined Forces With A Couple Of Companies Over Patient Data

Tempus has recently inked a deal with fellow data handling firms Precision HealthAI and CancerLinQ to make sense of the latter company’s mass of clinical and molecular information related to cancer patients. While simply obtaining such information is a task in and of itself, failing to analyze it won’t do any good for the world of healthcare or society at large.

As such, Tempus realized that it needed to serve CancerLinQ by building sufficient information technology infrastructure to analyze its hordes of information.

CancerLinQ’s clinical, molecular, and patient-related information has been pulled over the years from over a whopping 1 million patients, all of which were then currently affected by cancer or had been at some point in the past.

Chief Executive Officer of ASCO, the parent company of CancerLinQ LLC, Dr. Clifford Hudis reported that the conjunction of forces between Precision HealthAI and Tempus would allow the pair to analyze data more quickly, efficiently, and effectively than if their responsibilities were kept separate.

Eric Lefkofsky Recently Shared His Side Of The Deal In An Interview

Although the interview referenced herein wasn’t related directly to Tempus, ASCO, Precision HealthAI, or CancerLinQ, Mr. Eric Lefkofsky shared that ASCO had created CancerLinQ with the sole goal of amassing unbelievably large troves of personal, private, patient information from healthcare providers.

Most providers either delete such information after a certain time frame has passed, or keep them under digital lock and key, making it virtually impossible for any interested parties to gain access to such information.

While CancerLinQ was able to keep the information it garnered from healthcare facilities safe and secure, simply holding the informaiton wouldn’t help society or either company.

As such, an important question related to the information CancerLinQ possessed was, “What’s actually going to happen to CancerLinQ’s patient data?” Before Tempus and Eric Lefkofsky came along, the company had no clue as to what it would do with troves of cancer patients’ information. Even though the company had analytical tools of its own, it didn’t truly know how to treat such large amounts of data and even reasonably hope to make halfway-decent inferences from it.

What Society Can Take From The Partnership

Although no societal benefits will be produced immediately after the pair starts working with each other, inferences taken from the compound of information will likely aid in the development of prescription drugs, streamline clinical trials, and later make sense of the information it crunches.

Eric Lefkofsky’s Short Biography

Eric Lefkofsky kicked off his successful career with a bachelor’s and master’s degree from the world-renowned University of Michigan. He’s started several companies thoughout his career, most notably Groupon in 2008.